Today: 10 June 2026
Browse Category

NASDAQ:GH 30 October 2025 - 5 May 2026

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx shares dropped 51% to $33.12 after the company cut its 2026 revenue forecast and lowered full-year guidance to $475–$490 million. First-quarter revenue rose 17% to $102.3 million, but missed expectations as reimbursement rates and product mix hurt sales. The company posted an adjusted net loss of $8.2 million. Management maintained its target for positive adjusted net income this year.
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health shares jumped 7.2% to $109.24 Tuesday, nearing their 52-week high, despite Evercore ISI downgrading the stock while raising its price target to $105. A Form 4 filing showed Chief People Officer Terilyn J. Monroe received 17,555 shares through vested stock units. Shares have climbed about 200% in the past year. Investors are watching Medicare reimbursement rates for Guardant’s Shield blood test.
6 January 2026
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.

Stock Market Today

  • Live Cattle Futures Rise Amid Export Suspension and Mixed Beef Prices
    June 10, 2026, 11:20 AM EDT. Live cattle futures gained $1.50 to $2.97 on Tuesday, with feeder cattle futures climbing $2.00 to $3.45. Open interest dropped by 4,823 contracts. USDA estimated 109,000 cattle slaughtered on Tuesday, down from last year. Mexico suspended U.S. cattle imports due to screwworm cases, impacting exports which totaled 11,110 head in 2025. USDA boxed beef prices mixed: Choice beef rose $0.70 to $392.90, Select fell $1.16 to $376.93. The CME Feeder Cattle Index rose $5.63 to 367.01 on June 5. Pasture conditions improved slightly, with 31% rated good to excellent. Market watchers eye Wednesday trade for further direction in cattle futures amid these developments.

Latest articles

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

Dow Drops After CPI Surprise, Iran Concerns Keep Fed Outlook Uncertain

10 June 2026
Dow drops 0.55% to 50,592 after May CPI jumps 4.2% year-on-year, matching forecasts but fueled by a 7% surge in gasoline prices and rising energy costs, as renewed U.S.-Iran tensions and sharp losses in AI and industrial stocks add to investor caution, with Super Micro Computer plunging 14.2% on $7 billion equity plans and XPO, J.B. Hunt, Old Dominion falling up to 6.2% after Amazon expands freight service.
S&P 500 Swings After Hot CPI, AI Names Under Pressure

S&P 500 Swings After Hot CPI, AI Names Under Pressure

10 June 2026
May inflation jumped 4.2%—the fastest pace since April 2023—matching forecasts but keeping the Fed on hold, as energy prices fueled the rise; S&P 500 and Nasdaq steadied after early losses, but AI-linked stocks slid, with Super Micro Computer tumbling on a $7 billion share sale plan that risks diluting investors.
Chewy Drops After Q1 Beat With Outlook Warning

Chewy Drops After Q1 Beat With Outlook Warning

10 June 2026
Chewy slashed its 2026 net sales outlook to $13.40–$13.55 billion, below prior guidance and analyst estimates, sending shares down 50 cents to $19.90 as investors reacted to weaker-than-expected second-quarter forecasts despite a 7.7% first-quarter sales jump and improved profitability.
Go toTop